Milestone Pharmaceuticals
Yahoo Finance • 22 days ago
FDA Issues Complete Response Letter for Etripamil for PSVT
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmac... Full story
Yahoo Finance • last month
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) Assuming FDA approval, proposed launch in PSVT targeted for mid-2025 Milestone well-capitalized to com... Full story
Yahoo Finance • last month
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., March 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 94,000 optio... Full story
Yahoo Finance • 9 months ago
Milestone Pharmaceuticals Refreshes Board of Directors
Milestone Pharmaceuticals Inc. – Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -... Full story
Yahoo Finance • 2 years ago
Individual investors account for 48% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 38%
Key Insights Significant control over Milestone Pharmaceuticals by individual investors implies that the general public has more power to influence management and governance-related decisions 50% of the business is held by the top 25 shar... Full story
